drugset / Trial / NCT02354625

The Safety of ahSC in Chronic SCI With Rehabilitation

NCT02354625 ↗

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety of autologous human Schwann cell (ahSC) transplantation in participants with chronic SCI. This trial design is phase I, open label, unblinded, non-randomized, and non-placebo controlled multiple injury cohorts.

Timeline

Start
2015-01
Primary completion
2019-08-12
Completion
2019-08-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Autologous Human Schwann Cells Cell therapy — Other